Celltrion Is Latest To Settle Over Stelara

Deal With J&J Over CT-P43 Ustekinumab Biosimilar Offers Another 2025 Entry Date

 
• By Dave Wallace

Celltrion has become the latest biosimilars developer to announce a deal with J&J allowing it to launch a US ustekinumab biosimilar in early 2025. The Korean firm anticipates US FDA approval next year for its CT-P43 version.

Sprinter on starting blocks With 2025 text
Celltrion’s biosimilar is set to enter the market in 2025 • Source: Shutterstock

More from Deals

More from Business